Micro-Organics Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 2.40 Cr
- Company Age 18 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.93 Cr
- Satisfied Charges ₹ 7.70 M
- Revenue Growth 236.96%
- Profit Growth -140.64%
- Ebitda 1642.67%
- Net Worth 43.88%
- Total Assets 70.93%
About Micro-Organics Pharmaceuticals (India)
Micro-Organics Pharmaceuticals (India) Private Limited (MPIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 13 April 2006 and has a history of 18 years and ten months. Its registered office is in Allahabad, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.40 Cr.
The company currently has active open charges totaling ₹9.93 Cr. The company has closed loans amounting to ₹7.70 M, as per Ministry of Corporate Affairs (MCA) records.
Ram Babu, Dinesh Kumar, and Aditya Phougat serve as directors at the Company.
Company Details
- Location
Allahabad, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233UP2006PTC031611
- Company No.
031611
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Apr 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
What products or services does Micro-Organics Pharmaceuticals (India) Private Limited offer?
Micro-Organics Pharmaceuticals (India) Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Muscle Relaxant, Antipyretic Medication, Mefenamic Paracetamol Syrup, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Common Disease Medicines, Pharmaceutical Tablets, Vitamin B Complex Syrup, Betahistine Tablets.
Who are the key members and board of directors at Micro-Organics Pharmaceuticals (India)?
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Ram Babu ![]() | Director | 13-Apr-2006 | Current |
Dinesh Kumar ![]() | Director | 30-Jun-2023 | Current |
Aditya Phougat ![]() | Director | 30-Jun-2023 | Current |
Financial Performance of Micro-Organics Pharmaceuticals (India).
Micro-Organics Pharmaceuticals (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 236.96% increase. The company also saw a substantial fall in profitability, with a 140.64% decrease in profit. The company's net worth Soared by an impressive increase of 43.88%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Micro-Organics Pharmaceuticals (India)?
Unlock access to Micro-Organics Pharmaceuticals (India)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Charges (Loans)
₹9.93 Cr
₹0.77 Cr
Charges Breakdown by Lending Institutions
- Others : 9.93 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
14 Jun 2021 | Others | ₹9.93 Cr | Open |
08 Jun 2020 | Others | ₹1.00 M | Satisfied |
11 May 2020 | Others | ₹0.50 M | Satisfied |
09 Jun 2012 | Others | ₹5.00 M | Satisfied |
20 Sep 2008 | Bank Of Baroda | ₹1.20 M | Satisfied |
How Many Employees Work at Micro-Organics Pharmaceuticals (India)?
Unlock and access historical data on people associated with Micro-Organics Pharmaceuticals (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Micro-Organics Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Micro-Organics Pharmaceuticals (India)'s trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.